ArticleBriefings in bioinformatics2026
Multi-seed searching algorithm for integrated codon optimization of mRNA stability and translational efficiency in vaccine design.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Messenger RNA (mRNA) vaccines have revolutionized vaccinology with their rapid development cycles and adaptability, yet their broad application is constrained by unresolved challenges in balancing mRNA structural stability and translational efficiency. Here, we introduce a groundbreaking multi-seed searching algorithm for mRNA codon optimization, an innovative framework that synergistically co-optimizes minimum free energy and codon adaptation index through adaptive integration of simulated annealing and genetic algorithms. This novel approach enhances global search capability to escape local optima, a critical limitation of existing tools. Evaluations across long therapeutic mRNA sequences and short peptides (neoantigens from bladder cancer and melanoma) reveal our algorithm outperforms state-of-the-art LinearDesign, delivering superior balanced improvements in both stability and translational efficiency validating its unique ability to navigate the inherent trade-offs between these two key metrics. Built on this algorithm, the Optiseed platform introduces transformative features including customizable scoring functions, flexible parameters for tailored optimization, and support for integrating untranslated regions (UTRs), poly(A) tails, and other elements to enable end-to-end vaccine construct design. This innovation addresses the rigidity of conventional tools, empowering precise, context-specific optimization. Optiseed represents a robust, scalable solution for mRNA vaccine codon optimization. Its superior performance across diverse sequences underscores its potential to accelerate mRNA-based therapeutic development, particularly in personalized cancer immunotherapy, while offering a framework adaptable for other applications such as infectious disease vaccine design.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.